Wednesday, 25 September 2019

Atherectomy Devices Market 2019 - Opportunity, Driving Trends and deep study 2023

Market Scenario
Atherectomy devices are built to either shave, cut, vaporize, laser or sand the plaques. The devices come with different indications. Different atherectomy devices have been invented for commercial use. The location of the plaque and type of blockage influence the choice of atherectomy device to be used. Some atherectomy devices are used only in the larger arteries on the upper portion of the knee, while other devices come with smaller catheters that are suitable for operating the arteries below the knee.
Atherectomy is a technique applied to eliminate atherosclerotic plaque from affected arteries. The plaques are in either peripheral or coronary arterial vasculature and may have distinct characteristics depending on the nature of the plaque. Atherectomy is used widely in cure of both peripheral and coronary arterial ailments. It is a minimally invasive endovascular surgery.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7322
The worldwide Atherectomy devices market is likely to develop remarkably over the forecast period. It is projected that the global atherectomy devices market will register a CAGR of 6.12% over the forecast period of 2018–2023. In 2017, the estimated market value was around 1.09 billion.
The growing rate of peripheral and coronary arterial diseases coupled with increasing demand for minimally invasive techniques is predicted to boost the growth of the atherectomy devices market. Minimally invasive surgical techniques deliver quicker recovery, quick procedural time, lesser risk of infections and complications. The worldwide atherectomy devices market is likely to witness noteable surge in demand due to exponential growth in the incidence of lifestyle-related ailments and elderly population.
Segmentation
The global atherectomy devices market is segmented on the basis of product type, application, and end user.
Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.
The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.
On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific was projected to be the fastest growing region for the global atherectomy devices market. This owes to the technological advancements resulting in the development of cost-effective atherectomy devices leading to high acceptance rate for the devices in the Asia-Pacific region. The Middle East and Africa holds the least share in the global atherectomy devices market due to the presence of economically diverse countries, and less initiatives taken by the government.
It is projected that the Americas dominated the global atherectomy devices market owing to the growth of the market in the North American region. This is largely attributed to the factors such as increase in research funding, and growing awareness about the high-end atherectomy devices among medical professionals. Europe is expected to hold the second largest share in the atherectomy devices market owing to growing healthcare infrastructure. Additionally, various initiatives by public and private organizations is anticipated to boost the growth of the atherectomy devices market.
Browse Complete 160 Pages Premium Research Report @ https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Handheld Surgical Devices Market Definition, Symptoms and Treatments Review 2019

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Anti-Hypertensive Drugs Market over the forecast period. 
According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the market is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.
Competitive Analysis
Key players in the antihypertensive drugs market are Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan), Merck KGaA (Germany), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), and United Therapeutics Corporation (U.S.). The market is characterized by expiry of various patented drugs and entry of generics. Players are taking measures to regain their lost standing by investing in research and development and launch of new products.
Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.
The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.
Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.
Segmentation
The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation By Pharmacological Class               : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.
Segmentation By Hypertension Type                      : Comprises Systemic and Pulmonary Hypertension Drugs and other.
Segmentation By Disease Source                              : Comprises Primary and Secondary.
Segmentation By Regions                                            : Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Regional Analysis
The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.
The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.
The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @  https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Tuesday, 24 September 2019

Handheld Surgical Devices Market size and Key Trends in terms of volume and value 2019

Market Scenario:
The Global handheld surgical devices market is expected to grow at an approximate CAGR of 6.8% during forecast period, 2019–2023.
The hand held surgical devices are specially designed for specific surgeries. These are available in a wide variety of shapes and sizes.
Increasing number of surgical procedures is the key factor driving the handheld surgical devices market. According to the Australian Institute of Health and Welfare, during 2015–16, there were 10.6 million hospitalisations, and 1 in 4 hospitalisations involved a surgical procedure.
Various other factors such as increasing incidence of accidents, high geriatric population, technological advancements, increasing demand for plastic & reconstructive surgery, and rising patient awareness regarding the benefits of handheld surgical devices are also expected to propel the growth of the market.
Key players
Some of the key players in the global handheld surgical devices market are B. Braun Melsungen AG, Integra LifeSciences Corporation, Zimmer Biomet Holdings, Pelion Surgical, Medtronic, Smith & Nephew, Johnson & Johnson, Millennium Surgical Corp, Medicon Eg, Elite Medical, Becton, Dickinson and Company (BD), Thompson Surgical, Stryker, Aspen Surgical, KLS Martin, CooperSurgical Inc., and others.
Segmentation
The global handheld surgical devices market is segmented based on application, product, end user and region.
The global market for handheld surgical devices, by application is segmented into neurology, urology, orthopedics, gynecology, cardiovascular, wound closure, and others.
The market, by product, is segmented into forceps and spatulas, retractors, dilators, graspers, auxiliary devices, cutter devices, and others. The auxiliary devices segment is further classified as clamps, cannulas, and closure devices. The cutter devices segment is further classified as trocars, lancets, and scissor. The others segment includes punches, curettes, blunt dissectors, and snares.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centres, research and academic institutes, and others. Clinics held a lucrative market share in 2017 due to rising prevalence of chronic conditions.
Regional Analysis
The Americas dominated the global market for handheld surgical devices owing to the increasing prevalence of chronic conditions, and high geriatric population.
In 2017, it was estimated that Europe stood second in the global handheld surgical devices market. This can be attributed to the increasing cases of surgical procedures, and rising research and development investments. According to the 2016 data suggested by Eurostat, around 1040.8 cases of cataract surgery and 406.2 cases of transluminal coronary angioplasty are registered in Germany.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, increasing healthcare expenditure, a rising number of surgical procedures drive the regional markets of the Asia Pacific region. On the other hand, the Middle East and Africa held least share in the global handheld surgical devices market due to the low per capita income, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/handheld-surgical-devices-market-7210
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Recent Study Explores Cerebrospinal Fluid Management Devices Market Pipeline Review, 2019

Market scenario
Rising cases of hydrocephalus is one of the key factors driving the cerebrospinal fluid management (CSF) devices market. According to the Brain Foundation, one in every 1,000 Australian children is born with hydrocephalus annually.
Global cerebrospinal fluid management (CSF) devices market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 4.5% over the forecast period.
Various other factors such as rising research & development expenditure, geriatric population, technological advancements, growing adoption of minimally invasive procedures, and rising awareness about hydrocephalus are also expected to propel the growth of the market.
However, lack of trained professionals, side-effects associated with the treatment, and high cost of devices can hinder the market growth over the forecast period.
Key players
Medtronic plc, Integra LifeSciences Holdings Corporation, B. Braun Melsungen AG, DePuy Synthes, Spiegelberg GmbH & Co. KG, SOPHYSA, Natus Medical Incorporated, Dispomedica GmbH, Delta Surgical Limited, Argi Grup, Moller Medical GmbH, G. SURGIWEAR LTD., Wellong Instruments Co., Ltd., BeckerSmith Medical, Inc., and others.
Segmentation
The Global cerebrospinal fluid management (CSF) devices market is segmented based on product, age group, end user, and region.
The Global market for cerebrospinal fluid management (CSF) devices, by product is segmented into shunts, valve, and external drainage systems.
The shunts segment is further classified as ventriculoperitoneal (VP), ventriculoatrial (VA), lumboperitoneal (LP), and ventriculopleural (VPL). The valve segment is further classified as fixed, and adjustable. The external drainage systems segment is further classified as external ventricular drainage (EVD) systems, and lumbar drainage (LD) systems.
Based on age group, the market is segmented into paediatric, adult, and geriatric.
Based on end user, the market is segmented into hospitals, ambulatory settings, clinics, research and academic institutes, and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The cerebrospinal fluid management (CSF) devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European cerebrospinal fluid management (CSF) devices market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cerebrospinal fluid management (CSF) devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebrospinal fluid management (CSF) devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for cerebrospinal fluid management (CSF) devices owing to the rising geriatric population and presence of major market players. As per the 2018 statistics suggested by the U.S. Census Bureau, by 2035, there will be 78 million people 65 years and older compared to 76 million under the age of 18.
In 2017, it was estimated that Europe stood second in the global cerebrospinal fluid management (CSF) devices market. This can be attributed to the rising research and development investments and increasing technological advancements.
Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure and rising cases of hydrocephalus drives the regional markets of the Asia Pacific region. According to the Hydrocephalus association, approximately 200,000 cases of congenital hydrocephalus in infants are registered around the world. However, in India, nearly 12,000 cases of congenital hydrocephalus are registered each year.
On the other hand, the Middle East and Africa held least share in the global cerebrospinal fluid management (CSF) devices market due to the low per capita income and stringent government policies, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cerebrospinal-fluid-management-devices-market-7196
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wednesday, 18 September 2019

Top trends in Microbiology Testing Market by 2019

Market Scenario
The Global Microbiology Testing Market is expected to register 10.4% CAGR and is anticipated to reach USD 5409.1 6 Million by 2023. Microbiology testing services help to lower the potential damage risk by microbes and to ensure that the microbiology quality of the products is maintained. The microbial testing technique includes chemical, biological, biochemical, or molecular methods to quantify and identify microbes.
Technological advancements, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are the major drivers propelling market growth. However, erroneous results and high cost of reagents and instruments may constrain the growth of the market.
Key Players
The prominent players in the global microbiology testing market are, Beckman Coulter, Inc. (a subsidiary of Danaher Corp), BioMérieux SA, Thermo Fisher Scientific Inc., Cepheid (a subsidiary of Danaher), and F. Hoffmann-La Roche Ltd.
Some of the key strategies followed by the players operating in the global microbiology testing market were innovation, product development, acquisition, and expansion.
Market Dynamics
Technological advancements are expected to drive the growth of the market. For instance, according to the data published by the National Centre for Health Statistics in 2017, there were around 9,272 cases of tuberculosis infectious disease. Additionally, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are likely to support market growth. On the other hand, erroneous results and high cost of reagents and instruments are anticipated to hamper the market growth.
Segmentation
The global microbiology testing market has been segmented into product type, application, and end user. 
Based on type, the global market has been segmented into instruments, chemicals & reagents, consumables & accessories, and others. The instruments segment accounted for a market value of USD 954.9 million in 2016.
Based on application, the global market has been segmented into gastrointestinal infections, respiratory infections, urinary tract infections, sexually transmitted infections, and others.
Based on end user, the global market has been segmented into hospital associate laboratory, independent laboratory, and academic and research institutes.
Regional Analysis
The global microbiology testing market, based on region, is segmented into North Americas, Europe, Asia-Pacific, and the Middle East & Africa.
North America is estimated to dominate the global microbiology testing market during the forecast period. This can be attributed to the rapid adoption of advanced products and techniques. The European market for microbiology testing is expected to be the second-largest during the forecast period. Increasing innovation and changing laboratory practices is expected to boost the growth of the market in this region.
Asia-Pacific is estimated to be the fastest-growing market due to increasing funding for R&D, developing healthcare infrastructure, growing awareness about microbiology testing, government initiatives to improve public health, and growing investments by major players. Moreover, in the region, South Korea accounted for a market share of 9.2% in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, and limited availability to equipment.
Browse Premium Research Report with 129 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Age-Related Macular Degeneration Market Dynamics, Forecast, Analysis and Supply Demand 2019

Market scenario:
This MRFR study offers a vivid view of the global age-related macular degeneration AMD market. The study includes an in-depth analysis of macro and micro-economic factors likely to influence the market during the forecast period. It further summarizes the key market opportunities and trends.
The Global Age-Related Macular Degeneration Market is expected to register a CAGR of 7.80% to reach USD 11,186.8 Million by 2023. Age-related macular degeneration (AMD) is a chronic irreversible medical condition that results in central vision loss because of damage to the central area of the retina (macula). This condition is majorly categorized as dry age-related macular degeneration and wet age-related macular degeneration.
Growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off-patent are expected to enhance market growth. However, factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Key Players
The prominent players in the global age-related macular degeneration market are Novartis AG, Pfizer Inc, F. Hoffmann-La Roche AG, Acucela Inc., Ophthotech Corporation, GlaxoSmithKline PLC, Bayer AG, Rxi Pharmaceuticals, Inc., Regeneron Pharmaceutical Inc., Alimera Sciences Inc., Santen Pharmaceuticals Co., ALLERGAN, and Bausch & Lomb Incorporate.
Market Dynamics
The global age-related macular degeneration market has been primarily driven by growing geriatric population and increasing prevalence of age-related macular degeneration, several branded drugs going off patent. For instance, according to the 2017 statistics suggested by the United Nations, it was estimated that 962 million people aged 60 or above comprise 13% of the global population. Factors such as high cost associated with AMD, stringent FDA regulations may restrain the market growth during the forecast period.
Segmentation
The global age-related macular degeneration market has been segmented into type, stages, age group, treatment, and route of administration. Based on type, the market has been classified as wet age-related macular degeneration (wet AMD) and dry age-related macular degeneration (dry AMD). Dry age-related macular degeneration (dry AMD) held a market share of 2,092.6 USD million in 2017. Based on stages the market has been divided into intermediate-stage age-related macular degeneration, early-stage age-related macular degeneration, late-stage age-related macular degeneration. On the basis of age group, the market has been bifurcated into above 75 years, above 60 years, and 40 years. Based on treatment, the market has been divided into treatment and Diagnosis. Based on the route of administration, the market has been classified as an intravitreal route of administration and intravenous route of administration. Based on the end user, the market has been segmented into hospital & clinics, diagnostic centers, and academic research institutes.
Regional Analysis
The global age-related macular degeneration market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas dominate the global age-related macular degeneration market is owing to the rising ophthalmological disorders and increasing aging population. Nearly 7.3 million people are at significant risk of vision loss due to AMD.
Europe holds the second largest market share due to increasing older population and rising patient population. Additionally, improving government initiatives and increasing healthcare frame along with growing demand for technologically innovative treatment is driving the growth of age-related macular degeneration market in Europe
Asia-Pacific is estimated to be the fastest-growing region in the global age-related macular degeneration as it is developing at a very rapid pace and has shown the emergence of many players. Moreover, rising prevalence of eye disorders, increasing healthcare spending, and multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. Japan held a market share of 23.2% in 2017.
The Middle East & Africa are expected to witness restricted growth due to limited access and healthcare affordability among the population. In the Middle East, the growth of the market is driven by increasing healthcare infrastructure and healthcare expenditure.
Browse Complete 220 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/age-related-macular-degeneration-market-5736
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Liquid Biopsy Market 2019 Share, Trend, Segmentation and Forecast to 2023

Market Insights:
Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart.
Segmentation:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centres and others.
Major Players

  • Guardant Health, Inc.,
  • Trovagene, Inc.,
  • RainDance Technologies, Inc.,
  • Agena Bioscience Inc. Inc.,
  • Admera Health,
  • Biocept, Inc.,
  • Circulogene Theranostics,
  • Inivata Ltd.,
  • SAGA Diagnostics AB,
  • Exosome Diagnostics and others.

Drivers
The market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Also the technique is not applicable to all types of cancer as some cancers such as brain cancer and prostate cancer may lie dormant for many years, and thus are either undetectable or detected very late which robs liquid biopsy of its advantages. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.

Regional Analysis:
Depending on geographic region, Liquid biopsy market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The developing regions market such as Asia pacific region and Middle East & Africa however is rising much faster.
Key findings
  • Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
  • On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
  • The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Browse Complete 171 Pages Premium Research Report Enabled with 248 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com